NCT02269670 - Phase II Study of Everolimus Beyond Progression | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 25, 2014

Primary Completion Date

January 25, 2021

Study Completion Date

January 25, 2021

Conditions

Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerProgesterone Receptor-positive Breast CancerRecurrent Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer

Interventions

DRUG

everolimus

Given PO

DRUG

anastrozole

Given PO

DRUG

letrozole

Given PO

DRUG

tamoxifen citrate

Given PO

DRUG

fulvestrant

Given IM or PO

DRUG

megestrol acetate

Given PO

Trial Locations (3)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University/Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta